ARTICLE | Product Development
Ovid looks to broad path forward for rare epilepsy program
Phase II data show soticlestat reduces frequency of seizures in two additional disorders
September 30, 2020 10:18 PM UTC
Three years after striking a deal with Takeda to take the lead on developing the Japanese pharma’s soticlestat, Ovid is considering multiple paths to market for the therapy in rare epileptic encephalopathies.
On Wednesday, Ovid Therapeutics Inc. (NASDAQ:OVID) unveiled data from two open-label Phase II trials showing soticlestat reduced the frequency of epileptic seizures in patients with CDKL5 deficiency disorder and 15q duplication (Duq15q) syndrome. ...